These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10734761)

  • 1. [Sudden death and ventricular fibrillation of possible ischemic origin in a boy with hypertrophic myocardiopathy].
    Gutiérrez Díez A; Tamariz-Martel Moreno A; Baño Rodrigo A; Serrano González A
    Rev Esp Cardiol; 2000 Feb; 53(2):290-3. PubMed ID: 10734761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ventricular tachyarrhythmia associated with hypertrophic cardiomyopathy: incidence, prognosis, and relation to type of hypertrophy.
    Furushima H; Chinushi M; Iijima K; Sanada A; Izumi D; Hosaka Y; Aizawa Y
    J Cardiovasc Electrophysiol; 2010 Sep; 21(9):991-9. PubMed ID: 20487113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophic cardiomyopathy with midcavitary obstruction: another substrate for ventricular tachycardia?
    Gerstenfeld EP
    J Cardiovasc Electrophysiol; 2010 Sep; 21(9):1000-1. PubMed ID: 20487115
    [No Abstract]   [Full Text] [Related]  

  • 4. Multi-modality imaging in an exceptional case of aborted sudden cardiac death.
    Sonck J; Tanaka K; Czapla J; Vanderhasselt T; Kayaert P; Scott B; Sutherland G; Van Camp G
    Int J Cardiol; 2014 Feb; 171(2):e57-8. PubMed ID: 24365616
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar?
    Nishimura RA; Ommen SR
    JAMA; 2007 Jul; 298(4):452-4. PubMed ID: 17652299
    [No Abstract]   [Full Text] [Related]  

  • 6. Aborted sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Casey SA; Almquist AK
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):263. PubMed ID: 10090231
    [No Abstract]   [Full Text] [Related]  

  • 7. Sudden death as a presenting symptom of hypertrophic cardiomyopathy: treatment with an implantable cardioverter defibrillator.
    Talard P; Lévy S; Bonal J; Paganelli F; Bouchiat C; Cellarier G; Dussarat GV
    Pacing Clin Electrophysiol; 1996 Aug; 19(8):1264-7. PubMed ID: 8865227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-shock oversensing by a subcutaneous defibrillator resulting in inappropriate withholding of post-shock bradycardia pacing.
    Maass AH; Van Gelder IC
    Europace; 2014 Jul; 16(7):1032. PubMed ID: 24792457
    [No Abstract]   [Full Text] [Related]  

  • 11. Brugada syndrome and vasospasitc angina do coexist: potential clinical importance.
    Aizawa Y; Sato A
    Intern Med; 2006; 45(2):43-4. PubMed ID: 16484737
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy.
    Christiaans I; Lekanne dit Deprez RH; van Langen IM; Wilde AA
    Heart Rhythm; 2009 Sep; 6(9):1366-9. PubMed ID: 19539541
    [No Abstract]   [Full Text] [Related]  

  • 14. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-Related Cardiotoxicity.
    Trachtenberg B; Hussain F; Mukherjee A; Araujo-Gutierrez R; Pingali SRK
    Methodist Debakey Cardiovasc J; 2018; 14(3):e1-e4. PubMed ID: 30410661
    [No Abstract]   [Full Text] [Related]  

  • 17. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy.
    Maron BJ; Estes NA; Maron MS; Almquist AK; Link MS; Udelson JE
    Circulation; 2003 Jun; 107(23):2872-5. PubMed ID: 12814983
    [No Abstract]   [Full Text] [Related]  

  • 18. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. J Waves for Predicting Cardiac Events in Hypertrophic Cardiomyopathy.
    Tsuda T; Hayashi K; Konno T; Sakata K; Fujita T; Hodatsu A; Nagata Y; Teramoto R; Nomura A; Tanaka Y; Furusho H; Takamura M; Kawashiri MA; Fujino N; Yamagishi M
    JACC Clin Electrophysiol; 2017 Oct; 3(10):1136-1142. PubMed ID: 29759496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.